Ting Xu

Company: Alphamab Oncology

Job title: Chairman, Chief Executive Offier, Executive Director & Founder

Seminars:

Development of KN046, a PD-L1/CTLA-4 Bispecific, for Pancreatic Cancer 4:00 pm

Design of KN046 to reduce on target toxicity Dual ICI blocking demonstrated Significant anti-tumor activity with acceptable safety profile Early but promising sign of clinical activity in 1st pancreatic cancer seen in phase II trialRead more

day: Day One